Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F11%3A43870423" target="_blank" >RIV/62157124:16370/11:43870423 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.3109/03639045.2011.560156" target="_blank" >http://dx.doi.org/10.3109/03639045.2011.560156</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3109/03639045.2011.560156" target="_blank" >10.3109/03639045.2011.560156</a>
Alternative languages
Result language
angličtina
Original language name
Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease
Original language description
Background: In recent years, many achievements have been realized in the therapy of inflammatory bowel disease (IBD) although its etiology remains unknown. Thus IBD treatment is symptomatic and targets general inflammatory mechanisms. Oral formulations containing 5-aminosalicylic acid (5-ASA) have become the standard therapy for mild-to-moderate IBD. Objective: This article is a review of recently published research dealing with new 5-ASA dosage forms. Thus promising candidates for IBD treatment evaluated in vitro are reported; systems tested in vivo in trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats are mentioned; and 5-ASA formulations used in clinical studies are presented. Moreover, all oral dosage forms containing 5-ASA or its prodrugs are reviewed; their characteristics and utilization in IBD treatment are discussed. Conclusion: In several clinical studies, it has been shown that multiparticulates such as pellets offer more advantages as compared with single unit for
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Drug Development and Industrial Pharmacy
ISSN
0363-9045
e-ISSN
—
Volume of the periodical
37
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
1100-1109
UT code for WoS article
000293543700012
EID of the result in the Scopus database
—